Back to mobile site

More on ARVN

- Summary
- Chart
- Profile
- Historical

Data

- Earnings (-77.1% Growth)
- Ratings (6.0 Score)

Upcoming Events

- Earnings (11/10/26)

News

- Analyst Ratings
- Earnings Related
- Guidance
- Insider Trades
- Mgmt Changes
- M & A
- Retail Sales
- Rumors
- Stock Buybacks
More...

Arvinas Inc. (NQ:ARVN)
Delayed: 7.64 +0.13 (1.73%)
Prev. Close $7.51  
Open$7.46 
52 Wk High$ 
52 Wk Low$ 
Day High$7.74 
Day Low$7.46 
P/E N/A  
EPS$ 
Volume560,049 

Friends, Peers and Foes (?): PFE, ALNY, ARWR, CAPR, CRSP (more...)

Oct 7, 2026 07:00 AM Arvinas shares Phase 1 ARV-102 data for Parkinson's disease
Oct 7, 2026 07:00 AM Arvinas Shares Novel Oculomotor and Biomarker Data from Phase 1 Clinical Trial of ARV-102 in Patients with Parkinson’s Disease
Oct 1, 2026 04:01 PM Arvinas to present ARV-102 Parkinson's trial data at MDS congress
Oct 1, 2026 04:01 PM Arvinas to Present Novel Biomarker Data from the Phase 1 Clinical Trial for ARV-102, a PROTAC LRRK2 Degrader, at the 2026 International Congress of Parkinson’s Disease and Movement Disorders®
Sep 29, 2026 04:01 PM Arvinas Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Sep 28, 2026 04:03 PM Form S-8 ARVINAS, INC.
Sep 28, 2026 07:00 AM Arvinas doses first patient in ARV-6723 Phase 1/2 trial
Sep 28, 2026 07:00 AM Arvinas Announces First Patient Dosed in Phase 1/2 Clinical Trial of ARV-6723, the Company’s First Immuno-Oncology Candidate
Sep 22, 2026 04:36 PM Form 144 ARVINAS, INC. Filed by: AGARWAL SUNIL
Sep 3, 2026 04:01 PM Arvinas to Participate in Upcoming Investor Conferences
View All Articles

Entities mentioned with ARVN

View All Entities